艾德生物(300685) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥272,090,793.91, representing a 16.63% increase compared to ¥233,288,808.06 in the same period last year[5] - Net profit attributable to shareholders was ¥90,471,778.52, a 40.92% increase from ¥64,199,068.03 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥87,223,537.32, up 53.07% from ¥56,981,941.60 in the previous year[5] - Basic and diluted earnings per share were both ¥0.23, a 43.75% increase from ¥0.16 in the previous year[5] - Total operating revenue for the current period reached ¥272,090,793.91, an increase of 16.6% compared to ¥233,288,808.06 in the previous period[20] - Net profit for the current period was ¥90,471,778.52, representing a significant increase of 40.9% from ¥64,199,068.03 in the previous period[21] - The company's profit before tax was ¥101,793,500.12, an increase of 38.3% from ¥73,566,224.34 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities was ¥103,254,852.84, reflecting a 28.14% increase compared to ¥80,577,903.10 in the same period last year[5] - Operating cash flow increased to 103,254,852.84 from 80,577,903.10, a rise of 28.06%[22] - Total cash inflow from operating activities reached 290,859,140.41, compared to 273,690,053.97 in the previous period, marking a 6.25% increase[22] - Cash and cash equivalents at the end of the period decreased to 288,933,634.09 from 323,750,184.55, a drop of 10.76%[23] - The company reported a net increase in cash and cash equivalents of -26,528,201.73, contrasting with a net increase of 122,672,317.88 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,163,512,829.30, a 4.78% increase from ¥2,064,801,711.06 at the end of the previous year[5] - Total liabilities rose to ¥244,665,855.76, compared to ¥221,536,953.20, indicating an increase of 10.4%[18] - The company's total assets increased to ¥2,163,512,829.30 from ¥2,064,801,711.06, marking a growth of 4.8%[18] - Total current assets increased to ¥1,891,421,886.64 from ¥1,788,399,896.77[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 24,012[12] - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 22.31% of shares, totaling 87,701,616 shares[12] - The total number of shares held by the top ten unrestricted shareholders is 87,701,616, with Forward Investment (Hong Kong) Limited being the largest[13] - The total number of restricted shares at the end of the period is 3,464,606, down from 3,527,230 due to the unlocking of shares[14] - The company has no reported related party relationships or concerted actions among the top shareholders[13] Expenses and Investments - Total operating costs amounted to ¥171,878,070.83, up from ¥167,788,210.58, reflecting a growth of 1.3%[20] - Research and development expenses were ¥41,536,126.88, a decrease of 14.1% from ¥48,363,080.43 in the previous period[20] - The company has a long-term investment of ¥10,497,291.81, down from ¥11,951,810.18[16] - The financial expenses showed a significant improvement, with a net income of -¥10,374,808.85 compared to -¥3,263,353.11 previously[20] Future Plans and Accounting Changes - The company plans to continue its market expansion and product development strategies, although specific details were not disclosed in the provided content[15] - The company plans to adopt new accounting standards starting in 2025, which may impact future financial reporting[24] - The first quarter report was not audited, indicating a preliminary assessment of financial performance[24]